FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC

FDA Grants Breakthrough Therapy Designation to Durvalumab for NSCLC

The FDA granted breakthrough therapy designation to durvalumab for patients with locally advanced, unresectable NSCLC who do not relapse after platinum-based chemoradiation.

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

The addition of galunisertib to gemcitabine demonstrated improved overall and progression-free survival in pancreatic cancer.

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

Neoadjuvant ado-trastuzumab emtansine (T-DM1) combined with pertuzumab substantially improved pathologic complete response rates.

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

Monotherapy with labetuzumab govitecan is active in heavily pretreated patients with metastatic colorectal cancer (mCRC).

Entinostat May Improve Benefit of High-dose IL-2 in RCC

Entinostat May Improve Benefit of High-dose IL-2 in RCC

Entinostat may synergistically improve the therapeutic effect of high dose interleukin-2 (IL-2) in treatment-naïve clear cell renal cell carcinoma (RCC).

Crizotinib Active in MET+ Papillary mRCC Type 1

Crizotinib Active in MET+ Papillary mRCC Type 1

Crizotinib induces objective responses and long-lasting disease control in metastatic papillary renal cell carcinoma type 1 (PRCC1).

Certain Bacteria Linked to Elevated Risk of Pancreatic Cancer

Certain Bacteria Linked to Elevated Risk of Pancreatic Cancer

The presence of 2 species of bacteria was associated with an elevated risk for developing pancreatic cancer.

Study Assesses Mechanisms Behind Ibrutinib Resistance in CLL

Study Assesses Mechanisms Behind Ibrutinib Resistance in CLL

Most patients with progressive chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy harbor BTK and/or PLCG2 mutations.

PD-L1 Positivity Associated With Improved Efficacy of Pembrolizumab vs Ipilimumab

PD-L1 Positivity Associated With Improved Efficacy of Pembrolizumab vs Ipilimumab

Programmed death-ligand 1 (PD-L1) positivity is associated with improved efficacy with pembrolizumab in patients with advanced melanoma.

Pembrolizumab Resulted in Durable Responses in Advanced Merkel Cell Carcinoma

Pembrolizumab Resulted in Durable Responses in Advanced Merkel Cell Carcinoma

First-line therapy with pembrolizumab yielded frequent and durable response in patients with advanced Merkel cell carcinoma.

Nivolumab Improves Survival in Head and Neck Cancer

Nivolumab Improves Survival in Head and Neck Cancer

Nivolumab improved overall survival in patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma

Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma

After 5 years of follow-up, 34% of patients with advanced melanoma who participated in a phase 1 clinical trial are still alive after receiving nivolumab treatment.

Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer

Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer

Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.

MammaPrint Test Reduces Use of Adjuvant Chemo Among Patients With Early-stage Breast Cancer

MammaPrint Test Reduces Use of Adjuvant Chemo Among Patients With Early-stage Breast Cancer

The MammaPrint genetic test can reduce the use of adjuvant chemotherapy following surgery among patients with early-stage breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs